New Nonprofit Launches to Develop Peptide Compounding Quality Standards

A new independent nonprofit, formally the Pharmacy Compounding Accreditation Council (PCAC) and operating as the Peptide Council, launched July 27, 2026, with a mission to develop the first peptide-specific accreditation standards for compounding pharmacies, active pharmaceutical ingredient (API) suppliers, and telemedicine companies serving the peptide therapy market, according to PCAC (Madeleine Budge, 10 to 1 Public Relations, written communication July 27, 2026).

The organization, incorporated in Delaware as a 501(c)(3), has seated an interim board of directors charged with developing the accreditation framework and hiring a founding CEO.

A Market at an Inflection Point

The launch comes just days after the FDA's Pharmacy Compounding Advisory Committee, which was set to consider whether 7 peptide substances should be added to the agency's 503A Bulks List,¹ voted to recommend 6 of the 7 for inclusion—overriding FDA staff scientists who had recommended against adding any of them—while rejecting only emideltide.² The committee's recommendation is nonbinding; the FDA must still decide whether to accept it and complete the applicable regulatory process before any changes to the 503A Bulks List take effect. The timing coincides with heightened regulatory attention on compounded peptide therapies and a market the Peptide Council says has outgrown the existing mechanisms available to verify quality, according to PCAC.

The Council's proposed standards span the full peptide supply chain, including API sourcing and supplier qualification, standardized Certificates of Analysis from accredited testing laboratories, uniform labeling and dosing information, documented adverse event tracking, standards intended to limit marketing claims that extend beyond appropriate compounding practice, and accreditation criteria for telemedicine companies that prescribe compounded peptides.

"The compounding industry has seen what happens when a fast-growing market outpaces its quality infrastructure," said Lee Rosebush, chair of the Peptide Council Interim Board, in a statement. “Most compounding issues are not caused by the quality compounders doing the work right—it was caused by bad actors operating without meaningful oversight and by a regulatory environment that has no mechanism to tell the difference. The Peptide Council exists to make sure that does not happen to peptide therapy."

How PCAC Fits Alongside Existing Oversight

The accreditation is designed to complement, rather than replace, the oversight that already applies to compounders. Shawn Hodges, PharmD, CEO of Revelation Pharma, a national network of 503A and 503B compounding pharmacies, said the Peptide Council is intended to address a peptide-specific gap within the current regulatory and accreditation landscape.

“The Peptide Council is a standard-setting organization focused on the full peptide compounding supply chain, ranging from API sourcing through patient dispensing—we call it ‘Powder to Patient’,” Hodges told The American Journal of Managed Care^® (AJMC^®). “While state boards, the FDA’s 503A/503B framework, and accreditors like ACHC [Accreditation Commission for Health Care] each operate within defined lanes that stop at the pharmacy level, they apply general compounding standards. The Council seeks to provide peptide-specific criteria. Since there are many nuances to compounding peptides, from sourcing to compounding process to stability testing, the Council is designed to fill that gap by developing peptide-specific quality standards. The Council seeks to work with established accreditors as inspection partners at the pharmacy level rather than duplicating their infrastructure.”

The Accreditation Commission for Health Care’s Pharmacy Compounding Accreditation Board credential, the accreditation most commonly associated with compounding pharmacies, includes more than 900 accredited pharmacies nationwide.³

Governance and Timeline

To guard against conflicts of interest, the Council says a majority of its permanent board will hold no financial stake in compounding pharmacy operations and that the organization will be funded solely through accreditation fees rather than donations, according to PCAC. Inspections will be conducted directly or through contracted partner agencies, with the Council retaining sole authority over standards development and accreditation decisions.

“The Council has received expressions of interest from 20-plus compounding pharmacies to date and is targeting inspections later this year as it finalizes its standards framework and inspection partnerships,” said Hodges. “Until Council accreditation is available, prescribers and payers should look for 503B registration with the FDA as the highest current regulatory bar or third-party accredited 503A compounders. Beyond accreditation status, they should request from the pharmacy Certificates of Analysis that validate the quality of the ingredients (APIs) and/or ask the pharmacy to document its API supplier qualification process.”

References

1. Steinzor P. FDA advisory panel weighs access to 7 popular peptides this week. AJMC. July 23, 2026. Accessed August 5, 2026. https://www.ajmc.com/view/fda-advisory-panel-weighs-access-to-7-popular-peptides-this-week
2. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC. July 31, 2026. Accessed August 5, 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
3. ACHC partners with the International Academy of Compounding Pharmacists. News release. Pharmacy Times^®. April 15, 2015. Accessed August 5, 2026. https://www.pharmacytimes.com/view/achc-partners-with-the-international-academy-of-compounding-pharmacists